155 related articles for article (PubMed ID: 37256433)
1. Estimating Transition Probabilities Across the Alzheimer's Disease Continuum Using a Nationally Representative Real-World Database in the United States.
Tahami Monfared AA; Fu S; Hummel N; Qi L; Chandak A; Zhang R; Zhang Q
Neurol Ther; 2023 Aug; 12(4):1235-1255. PubMed ID: 37256433
[TBL] [Abstract][Full Text] [Related]
2. Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data.
Potashman M; Buessing M; Levitchi Benea M; Cummings J; Borson S; Pemberton-Ross P; Epstein AJ
Neurol Ther; 2021 Dec; 10(2):941-953. PubMed ID: 34431074
[TBL] [Abstract][Full Text] [Related]
3. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
[TBL] [Abstract][Full Text] [Related]
4. Relationships of change in Clinical Dementia Rating (CDR) on patient outcomes and probability of progression: observational analysis.
Tariot PN; Boada M; Lanctôt KL; Hahn-Pedersen J; Dabbous F; Udayachalerm S; Raket LL; Halchenko Y; Michalak W; Weidner W; Cummings J
Alzheimers Res Ther; 2024 Feb; 16(1):36. PubMed ID: 38355706
[TBL] [Abstract][Full Text] [Related]
5. Understanding the role of psychiatrists in the diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: a cross-sectional survey.
Gopalakrishna G; Brunton S; Pruzin J; Alford S; Hamersky C; Sabharwal A
BMC Psychiatry; 2023 Oct; 23(1):716. PubMed ID: 37794326
[TBL] [Abstract][Full Text] [Related]
6. Multi-state Markov model in outcome of mild cognitive impairments among community elderly residents in Mainland China.
Yu HM; Yang SS; Gao JW; Zhou LY; Liang RF; Qu CY
Int Psychogeriatr; 2013 May; 25(5):797-804. PubMed ID: 23286508
[TBL] [Abstract][Full Text] [Related]
7. Assessing out-of-pocket expenses and indirect costs for the Alzheimer disease continuum in the United States.
Monfared AAT; Hummel N; Chandak A; Khachatryan A; Zhang Q
J Manag Care Spec Pharm; 2023 Sep; 29(9):1065-1077. PubMed ID: 37307097
[No Abstract] [Full Text] [Related]
8. Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.
Neumann PJ; Araki SS; Arcelus A; Longo A; Papadopoulos G; Kosik KS; Kuntz KM; Bhattacharjya A
Neurology; 2001 Sep; 57(6):957-64. PubMed ID: 11571317
[TBL] [Abstract][Full Text] [Related]
9. [Multi-state model in the evaluation of outcome on mild cognitive impairment to Alzheimer's disease].
Gao JW; Yang SS; Zhou LY; Wang XC; Gao CH; Song PP; Yu HM
Zhonghua Liu Xing Bing Xue Za Zhi; 2012 May; 33(5):470-3. PubMed ID: 22883171
[TBL] [Abstract][Full Text] [Related]
10. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.
Spackman DE; Kadiyala S; Neumann PJ; Veenstra DL; Sullivan SD
Curr Alzheimer Res; 2012 Nov; 9(9):1050-8. PubMed ID: 22175655
[TBL] [Abstract][Full Text] [Related]
11. Medical Journey of Patients with Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia: A Cross-sectional Survey of Patients, Care Partners, and Neurologists.
Pruzin JJ; Brunton S; Alford S; Hamersky C; Sabharwal A; Gopalakrishna G
J Prev Alzheimers Dis; 2023; 10(2):162-170. PubMed ID: 36946442
[TBL] [Abstract][Full Text] [Related]
12. Risk factors of transition from mild cognitive impairment to Alzheimer's disease and death: A cohort study.
Xue H; Sun Q; Liu L; Zhou L; Liang R; He R; Yu H
Compr Psychiatry; 2017 Oct; 78():91-97. PubMed ID: 28806610
[TBL] [Abstract][Full Text] [Related]
13. Perspectives of patients, care partners, and primary care physicians on management of mild cognitive impairment and mild Alzheimer's disease dementia.
Brunton S; Pruzin JJ; Alford S; Hamersky C; Sabharwal A; Gopalakrishna G
Postgrad Med; 2023 Jun; 135(5):530-538. PubMed ID: 37219410
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Cost-effectiveness of a Hypothetical Disease-modifying Therapy With Limited Duration for the Treatment of Early Symptomatic Alzheimer Disease.
Boustani M; Doty EG; Garrison LP; Smolen LJ; Belger M; Klein TM; Murphy DR; Burge R; Wall JK; Johnston JA
Clin Ther; 2022 Nov; 44(11):1449-1462. PubMed ID: 36210219
[TBL] [Abstract][Full Text] [Related]
15. [Competing risk model based study of outcomes of mild cognitive impairment of seniors].
Sun Q; Song Y; Kong P; Yu H
Zhonghua Liu Xing Bing Xue Za Zhi; 2015 Mar; 36(3):241-4. PubMed ID: 25975401
[TBL] [Abstract][Full Text] [Related]
16. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MGEKN; Tabet N
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002854. PubMed ID: 28418065
[TBL] [Abstract][Full Text] [Related]
17. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
Farina N; Llewellyn D; Isaac MG; Tabet N
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002854. PubMed ID: 28128435
[TBL] [Abstract][Full Text] [Related]
18. Souvenaid for Alzheimer's disease.
Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
[TBL] [Abstract][Full Text] [Related]
19. Estimating the risk for conversion from mild cognitive impairment to Alzheimer's disease in an elderly Arab community.
Inzelberg R; Massarwa M; Schechtman E; Strugatsky R; Farrer LA; Friedland RP
J Alzheimers Dis; 2015; 45(3):865-71. PubMed ID: 25624416
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
